Lifonebart (VHB937) vs SAR448851
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Alzheimer's Disease
Shared mechanism: TREM2 · full Alzheimer's Disease pipeline
Lifonebart (VHB937)
Developed by Novartis
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2028 · NCT07094516 (registry estimate)
No aligned efficacy figure on record for this race.
SAR448851
Developed by Sanofi and partners
NCT06343636 · Phase 1 · completed
The healthy-volunteer part of this trial randomly assigned participants to VG-3927 or a matching placebo under double-blind conditions, which is a real controlled design, but the Alzheimer's disease group received a single open-label dose with no comparator. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Adverse Events". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: July 2029 · NCT07688213 (registry estimate)
Reported efficacy
Adverse Events (28 days post last dose): The phase 1 trial enrolled 115 participants across multiple cohorts to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of VG-3927. VG-3927 achieved a robust and dose-dependent reduction of soluble TREM2 of up to approximately 50% in cerebrospinal fluid, with the maximum reduction of approximately 50% at the 25 mg dose. All related adverse events were mild or moderate in severity and self-resolving without drug discontinuations, and no serious adverse events were reported.
Result source: NCT06343636
Results for Alzheimer's Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Lifonebart (VHB937) | SAR448851 |
|---|---|---|
| CDR-SB, change | —Not reported | —Not reported |
| ADAS-Cog11, change | —Not reported | —Not reported |
| ADCS-ADL, change | —Not reported | —Not reported |
| MMSE, change | —Not reported | —Not reported |
| Amyloid PET, change (centiloids) | —Not reported | —Not reported |
CDR-SB, change
- Lifonebart (VHB937)
- —Not reported
- SAR448851
- —Not reported
ADAS-Cog11, change
- Lifonebart (VHB937)
- —Not reported
- SAR448851
- —Not reported
ADCS-ADL, change
- Lifonebart (VHB937)
- —Not reported
- SAR448851
- —Not reported
MMSE, change
- Lifonebart (VHB937)
- —Not reported
- SAR448851
- —Not reported
Amyloid PET, change (centiloids)
- Lifonebart (VHB937)
- —Not reported
- SAR448851
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Lifonebart (VHB937): no structured comparison results are available for Alzheimer's Disease.
SAR448851: no structured comparison results are available for Alzheimer's Disease.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Lifonebart (VHB937)'s landscape · SAR448851's landscape